Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comparison of quantitative results obtained with the Enzygnost antiVZV/IgG, Serion ELISA Classic VZV IgG, and Euroimmun anti-VZV ELISA (IgG) tests for.

Published byIrma Caitlin Matthews Modified over 5 years ago

Similar presentations

Presentation on theme: "Comparison of quantitative results obtained with the Enzygnost antiVZV/IgG, Serion ELISA Classic VZV IgG, and Euroimmun anti-VZV ELISA (IgG) tests for."— Presentation transcript:

1 Comparison of quantitative results obtained with the Enzygnost antiVZV/IgG, Serion ELISA Classic VZV IgG, and Euroimmun anti-VZV ELISA (IgG) tests for positive sera from blood donors of panel 2. Comparison of quantitative results obtained with the Enzygnost antiVZV/IgG, Serion ELISA Classic VZV IgG, and Euroimmun anti-VZV ELISA (IgG) tests for positive sera from blood donors of panel 2. A total of 357 sera within the upper quantification limit of 2,000 mIU/ml for the Serion ELISA Classic VZV IgG were included. Correlation was analyzed statistically by Passing-Bablok regression. Andreas Sauerbrei et al. Clin. Vaccine Immunol. 2012; doi: /CVI

Download ppt "Comparison of quantitative results obtained with the Enzygnost antiVZV/IgG, Serion ELISA Classic VZV IgG, and Euroimmun anti-VZV ELISA (IgG) tests for."

Similar presentations

anti-hnRNP A2 (U/mL) anti-hnRNP B1 (U/mL)

anti-hnRNP A2 (U/mL) anti-hnRNP B1 (U/mL)
Shigella-specific serum IgG and IgA endpoint titers in guinea pigs immunized intranasally with S. flexneri 2a InvaplexNAT or InvaplexAR. Shigella-specific.

Shigella-specific serum IgG and IgA endpoint titers in guinea pigs immunized intranasally with S. flexneri 2a InvaplexNAT or InvaplexAR. Shigella-specific.
FMDV-specific IgG, IgG1, and IgG2 in sera of guinea pigs (n = 6/group) immunized on days 1 and 21 by intramuscular injection of FMDV antigens (type O)

FMDV-specific IgG, IgG1, and IgG2 in sera of guinea pigs (n = 6/group) immunized on days 1 and 21 by intramuscular injection of FMDV antigens (type O)
HA-specific Abs in serum 14 d after a single vaccination with the various targeted DNA vaccines. HA-specific Abs in serum 14 d after a single vaccination.

HA-specific Abs in serum 14 d after a single vaccination with the various targeted DNA vaccines. HA-specific Abs in serum 14 d after a single vaccination.
A single DNA vaccination of C57BL/6 mice induced Ab responses of IgG1 and/or IgG2c subclass. A single DNA vaccination of C57BL/6 mice induced Ab responses.

A single DNA vaccination of C57BL/6 mice induced Ab responses of IgG1 and/or IgG2c subclass. A single DNA vaccination of C57BL/6 mice induced Ab responses.
Virus-specific serum antibody response of BALB/c mice to DNA prime followed by VRP boost. Virus-specific serum antibody response of BALB/c mice to DNA.

Virus-specific serum antibody response of BALB/c mice to DNA prime followed by VRP boost. Virus-specific serum antibody response of BALB/c mice to DNA.
Protection from influenza virus challenge.

Protection from influenza virus challenge.
FMD VP1-specific IgG, IgG1, and IgG2 in sera of guinea pigs (n = 6/group) immunized on days 1 and 21 by intramuscular injection of FMDV antigens (type.

FMD VP1-specific IgG, IgG1, and IgG2 in sera of guinea pigs (n = 6/group) immunized on days 1 and 21 by intramuscular injection of FMDV antigens (type.
Identification of novel IgGs in alpaca serum.

Identification of novel IgGs in alpaca serum.
Detection of CSFV-specific antibodies in immunized/challenged pigs using blocking ELISA. Groups of pigs (n = 5) were inoculated with different doses of.

Detection of CSFV-specific antibodies in immunized/challenged pigs using blocking ELISA. Groups of pigs (n = 5) were inoculated with different doses of.
Virus-specific serum antibody response of BALB/c mice to DNA prime followed by VRP boost. Virus-specific serum antibody response of BALB/c mice to DNA.

Virus-specific serum antibody response of BALB/c mice to DNA prime followed by VRP boost. Virus-specific serum antibody response of BALB/c mice to DNA.
Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer

Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer
Ex vivo IL-6 production. Ex vivo IL-6 production. Human whole blood was stimulated with the indicated doses of the E. coli O113 endotoxin that was used.

Ex vivo IL-6 production. Ex vivo IL-6 production. Human whole blood was stimulated with the indicated doses of the E. coli O113 endotoxin that was used.
Immune response to vaccination with AVA in healthy human subjects (human immunogenicity study). Immune response to vaccination with AVA in healthy human.

Immune response to vaccination with AVA in healthy human subjects (human immunogenicity study). Immune response to vaccination with AVA in healthy human.
Figure 3 Effects of RTX on specific anti-pathogen IgGs

Figure 3 Effects of RTX on specific anti-pathogen IgGs
CCL19 levels are elevated in Lyme disease cases with PTLDS

CCL19 levels are elevated in Lyme disease cases with PTLDS
Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantification of HCV RNA. (A) Linear.

Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantification of HCV RNA. (A) Linear.
(Upper) Levels of antibodies (ELISA OD values) reactive with each of 16 recombinant proteins of S. zooepidemicus strain NC78 in 1:200 dilutions of convalescent-phase.

(Upper) Levels of antibodies (ELISA OD values) reactive with each of 16 recombinant proteins of S. zooepidemicus strain NC78 in 1:200 dilutions of convalescent-phase.
Tetramer staining performed to determine frequencies of epitope-specific T cells after clearance of HPV16 infection but prior to isolation of T-cell clones.

Tetramer staining performed to determine frequencies of epitope-specific T cells after clearance of HPV16 infection but prior to isolation of T-cell clones.
Comparison of relative activity of Adjuplex and other commonly used adjuvants. Comparison of relative activity of Adjuplex and other commonly used adjuvants.

Comparison of relative activity of Adjuplex and other commonly used adjuvants. Comparison of relative activity of Adjuplex and other commonly used adjuvants.

Similar presentations

Ads by Google